Positive results from Phase 2, open-label ENCORE 303 trial to be presented at ASCO 20

[News]

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, reported final results from the Phase 2, open-label ENCORE 303 trial in post-menopausal women with advanced, estrogen receptor positive breast cancer who were progressing on aromatase inhibitor therapy.

More... (http://www.news-medical.net/news/20100605/Positive-results-from-Phase-2-open-label-ENCORE-303-trial-to-be-presented-at-ASCO-2010.aspx)